Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jun 28;24(1):780.
doi: 10.1186/s12885-024-12561-7.

The predictive value of serum inflammatory markers for the severity of cervical lesions

Lin Qin  1 , Lina Zhang  2
Affiliations

The predictive value of serum inflammatory markers for the severity of cervical lesions

Lin Qin et al. BMC Cancer. .

Abstract

Objective: Exploring the predictive value of NLR, PLR, MLR, and SII for the severity of cervical cancer screening abnormalities in patients.

Methods: A retrospective analysis was conducted on the data of 324 patients suspected of cervical lesions due to abnormal TCT and/or HPV in our hospital from January 2023 to December 2023, who underwent colposcopy. The pathological results of colposcopic biopsy confirmed that there were 140 cases of chronic cervicitis, which classified as the group without cervical lesions. The cervical lesion group included 184 cases, including 91 cases of LSIL, 71 cases of HSIL, and 22 cases of cervical cancer. Compared the differences in preoperative peripheral blood NLR, PLR, MLR, and SII among different groups of patients, and evaluated their predictive value for the severity of cervical lesions using Receiver Operating Characteristic (ROC) curves.

Results: The levels of NLR, PLR, and SII in the group without cervical lesions were lower than those in the group with cervical lesions (p < 0.05), and there was no statistically significant difference in MLR (p > 0.05). The comparison of NLR among LSIL, HSIL, and cervical cancer groups showed statistically significant differences (p < 0.05), while PLR, MLR, and SII showed no statistically significant differences (p > 0.05). The AUC of peripheral blood NLR, PLR, and SII for predicting cervical lesions were 0.569, 0.582, and 0.572, respectively. The optimal cutoff values were 2.3,176.48, and 603.56. The sensitivity and specificity were 38.6% and 73.6%, 28.8% and 85.7%, 37.5% and 76.4%, respectively. At the same time, the joint testing of the three had the highest efficiency, with sensitivity of 69% and specificity of 45%.

Conclusion: Although the peripheral blood NLR, PLR, and SII of the cervical lesions patients were higher than those without cervical lesions in cervical cancer screening abnormal patients, the predictive ROC curve discrimination was low. Therefore, it is not recommended to use preoperative peripheral blood inflammatory markers as markers for cervical cancer screening abnormal patient diversion.

Keywords: Cervical lesions; Colposcopy; MLR; NLR; PLR; SII.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Comparison of onset age groups for LSIL, HSIL, and cervical cancer
Fig. 2
Fig. 2
Comparison of NLR among LSIL, HSIL, and cervical cancer groups
Fig. 3
Fig. 3
ROC curve for predicting cervical lesions using NLR, PLR, SII, and their combined detection
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Yang Q, Zhou Q, He X, et al. Retrospective analysis of the incidence and predictive factors of parametrial involvement in FIGO IB1 cervical cancer[J] J Gynecol Obstet Hum Reprod. 2021;50(8):102145. doi: 10.1016/j.jogoh.2021.102145. - DOI - PubMed
    1. Hall MT, Smith MA, Simms KT, et al. Elimination of cervical cancer in Tanzania: Modelled analysis of elimination in the context of endemic HIV infection and active HIV control[J] Int J Cancer. 2021;149(2):297–306. doi: 10.1002/ijc.33533. - DOI - PubMed
    1. Arbyn M, Weiderpass E, Bruni L, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis[J] Lancet Glob Health. 2020;8(2):e191–203. doi: 10.1016/S2214-109X(19)30482-6. - DOI - PMC - PubMed
    1. Blake J. The elimination of Cervical Cancer in our Lifetime[J] J Obstet Gynaecol Can. 2018;40(12):1555–7. doi: 10.1016/j.jogc.2018.08.019. - DOI - PubMed
    1. Taghavi K, Moono M, Asangbeh S, et al. Strengthening global commitment to eliminating cervical cancer: what lessons from the past can we apply to the future?[J] J Glob Health. 2020;10(2):20385. doi: 10.7189/jogh.10.020385. - DOI - PMC - PubMed

MeSH terms

Substances